Abstract:Objective To establish progestin-resistant models of human endometrial carcinoma xenografts,and explore the role of epidermal growth factor receptor(EGFR) signaling pathway in progestin resistance of human endometrial carcinoma xenografts.Methods Thirty-six nude mice were subcutaneously injected with human endometrial carcinoma progestin-sensitive Ishikawa cells(n=18) or progestin-insensitive Ishikawa-pLWERNL cells(n=18),and human endometrial carcinoma xenografts were formed.Then,both nude mice treated with Ishikawa cells and Ishikawa-pLWERNL cells were divided into three groups,respectively(n=6),and were managed with medroxyprogesterone acetate(MPA)(MPA group),gefitinib(gefitinib group) and normal saline(control group),respectively.After treatment,wet weight of xenografts was recorded,and the expression of EGFR,progesterone receptor B(PR-B),ERK1/2,p-ERK1/2,AKT and p-AKT protein in xenograft tissues was detected by Western blotting.Results In nude mice treated with Ishikawa cells,the wet weight of xenografts in MPA group and gefitinib group was 43.0% and 31.5% lower than that in control group,respectively(P0.05).In nude mice treated with Ishikawa-pLWERNL cells,the wet weight of xenografts in gefitinib group and MPA group was 35.7% and 2.9% lower than that in control group,respectively(P0.05 and P0.05).The expression of EGFR protein in xenograft tissues treated with Ishikawa-pLWERNL cells was significantly higher than that in xenograft tissues treated with Ishikawa cells(P0.05),while that was opposite for the expression of PR-B protein(P=0.000).In xenograft tissues treated with Ishikawa cells,the expression of PR-B protein in MPA group was significantly lower than that in control group(P0.01),while there was no significant difference between gefitinib group and control group(P0.05).In xenograft tissues treated with Ishikawa-pLWERNL cells,there was no significant difference in the expression of PR-B protein among groups(P0.05).In xenograft tissues treated with Ishikawa cells,the expression of p-ERK1/2 and p-AKT protein in gefitinib group was significantly lower than that in control group and MPA group(P0.05).In xenograft tissues treated with Ishikawa-pLWERNL cells,the expression of p-ERK1/2 and p-AKT protein in gefitinib group was significantly lower than that in control group(P0.05),and the expression of p-ERK1/2 and p-AKT protein in MPA group was significantly higher than that in control group(P0.01).Conclusion The over-expressed EGFR protein can downregulate the expression of PR-B protein in Ishikawa-pLWERNL xenografts,which results in insensitivity to MPA.Gefitinib,the EGFR tyrosine kinase inhibitors,can effectively inhibit the expression of p-ERK1/2 and p-AKT protein,especially in progestin-insensitive Ishikawa-pLWERNL xenografts.

Sterol Regulatory Element-Binding Protein–1/Fatty Acid Synthase Involvement in Proliferation Inhibition and Apoptosis Promotion Induced by Progesterone in Endometrial Cancer

Roles of SIRT1/FoxO1/SREBP-1 in the Development of Progestin Resistance in Endometrial Cancer

Repression of Endometrial Tumor Growth by Targeting SREBP1 and Lipogenesis

Involvement of Cyclin B1 in Progesterone-Mediated Cell Growth Inhibition, G2/M Cell Cycle Arrest, and Apoptosis in Human Endometrial Cell

Fatostatin reverses progesterone resistance by inhibiting the SREBP1-NF-κB pathway in endometrial carcinoma

Fatostatin Suppresses Growth and Enhances Apoptosis by Blocking SREBP-regulated Metabolic Pathways in Endometrial Carcinoma.

Megestrol acetate drives endometrial carcinoma cell senescence via interacting with progesterone receptor B/FOXO1 axis

Progesterone induces cell apoptosis via the CACNA2D3/Ca2+/p38 MAPK pathway in endometrial cancer

Investigations on the mechanism of progesterone in inhibiting endometrial cancer cell cycle and viability via regulation of long noncoding RNA NEAT1/microRNA-146b-5p mediated Wnt/β-catenin signaling

[Effects of ICI182780 (faslodex) on Proliferation and Apoptosis Induced by 17Beta-Estradiol in Endometrial Carcinoma Cells].

Epidermal Growth Factor Receptor Signaling Enhanced by Long-Term Medroxyprogesterone Acetate Treatment in Endometrial Carcinoma.

Forkhead Transcription Factor 1 Inhibits Endometrial Cancer Cell Proliferation Via Sterol Regulatory Element-Binding Protein 1.

[Study of Mechanism of Medroxyprogesterone 17-Acetate on the Cancer Stem Cell-Like Properties of Human Endometrial Cancer].

Comprehensive bioinformatics analysis of acquired progesterone resistance in endometrial cancer cell line

Functional Study of Progesterone Receptor Isoforms in Endometrial Cancer Cell Lines

[Influence of Long-Term Treatment with MPA on the Biological Character of Endometrial Carcinoma Ishikawa Cell].

Growth and Activation of PI-3K/PKB and Akt by Stromal Cell-Derived Factor 1α in Endometrial Carcinoma Cells with Expression of Suppressor Endoprotein PTEN

Progesterone Receptor-B Induction of BIRC3 Protects Endometrial Cancer Cells from AP1-59-Mediated Apoptosis

MPA influences tumor cell proliferation, migration, and invasion induced by RANKL through PRB involving the MAPK pathway in endometrial cancer.

Role of Epidermal Growth Factor Receptor Signaling Pathway in Progestin Resistance of Human Endometrial Carcinoma Xenografts

Overexpressed Epidermal Growth Factor Receptor (egfr)‐induced Progestin Insensitivity in Human Endometrial Carcinoma Cells by the EGFR/mitogen‐activated Protein Kinase Signaling Pathway